We operate our Discovery Biology services from our R and D centers in Hyderabad and Bangalore. The facilities are equipped to perform standalone services and integrated services across In vitro biology, DMPK, In vivo pharmacology, Microbiology and Toxicology services.
In vitro lab at Aurigene is equipped to perform standard and highly specialized biochemical and cell-based assays across different disease areas, multiple targets and a broad range of drug classes. In addition to the regular instruments like plate reader, biosafety cabinets, we have high end instruments for quantification of drug to protein interaction.
DMPK lab infrastructure covers a lab area of 10,000 sq.ft. with in vitro ADME and tissue culture labs. We operate GLP as well as Non-GLP bio analytical labs with high-end instruments including LC-MS/MS, Sciex API, Waters Xevo TQS, HPLCs/UFLCs with UV, PDA and fluorescence detectors. The in vivo and PK studies are conducted in AAALAC accredited animal facilities. In addition to the above, we also have a compound management and data automation system set up for DMPK.
We have an AAALAC & CPCSEA accredited animal facility through which we can handle 600 rodents at any given time. We have more than 50 in vivo efficacy validated models available for testing. We provide PK/ PD correlation studies, biomarkers establishment studies across various targets and have advanced equipment for testing of compounds at early-stage drug discovery including anesthesia machine, electronic vonfrey, randall-sielto, capacitance meter, plethismomteter. We have completed 1000+ efficacy studies including submissions to the US FDA and DCGI.
Our microbiology laboratory is biosafety Level 2 compliant, and it has been audited by US FDA in 2019 with Zero 483 observations. The labs are well equipped with all required instruments like biosafety cabinets, shaking incubator, carbon dioxide incubator, spectrophotometer, microscope and automatic microbial colony counter. We have a media laboratory where all types of microbiological media are prepared in-house using dehydrated powders.
We offer broad range of toxicology services from our GLP certified toxicology lab. We have an experience of conducting more than 9000 toxicity studies during the past 20 years. All toxicology studies are conducted in accordance with national and international test guidelines and in compliance with OECD principles of Good Laboratory Practice (GLP). The animal toxicity studies include short and long term non-GLP exploratory and GLP IND toxicity studies. The tests are carried out in rats and mice, and are maintained individually in ventilated cages. Our animal facility is AAALAC accredited. Our expert team of scientists are proficient in conducting assays such as bacterial reverse mutation test, in vivo and in vitro micronucleus test, in vivo and in vitro chromosomal aberration test. Clinical pathology laboratory is well equipped with fully automated analyzers for hematology, coagulation, clinical chemistry, and urine analysis. Histopathology laboratory is well equipped with state-of-the-art instruments to prepare good quality slides for various organs and tissues collected from experimental animals. These histopathology slides are examined microscopically by expert veterinary pathologists for safety evaluation of test articles. Apart, from standard toxicity assays, we also perform customized toxicity studies as proposed by the sponsors.
JUNE 28, 2022
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...Read More
JANUARY 04, 2021
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...Read More
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...Read More
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.